Digital pathology in personalized cancer therapy
Janina Słodkowska1, Marcial Garcia Rojo
1Department of Pathology, Military Institute of Medicine, Warsaw, Poland. joanslo@wp.pl
Abstract:
The development of small molecule inhibitors of growth factor receptors, and the discovery of somatic mutations of the tyrosine kinase domain, have resulted in new paradigms for cancer therapy. Digital microscopy is an important tool for surgical pathologists. The achievements in the digital pathology field have modified the workflow of pathomorphology labs, enhanced the pathologist's role in diagnostics, and increased their contribution to personalized targeted medicine. Digital image analysis is now available in a variety of platforms to improve quantification performance of diagnostic pathology. We here describe the state of digital microscopy as it applies to the field of quantitative immunohistochemistry of biomarkers related to the clinical personalized targeted therapy of breast cancer, non-small lung cancer and colorectal cancer: HER-2, EGFR, KRAS and BRAF genes. The information is derived from the experience of the authors and a review of the literature.
Insights
Digital microscopy enhances cancer diagnosis by enabling quantitative immunohistochemistry for targeted therapies. This technology improves biomarker analysis for breast, lung, and colorectal cancers, aiding personalized medicine.
Area of Science:
- Oncology
- Pathology
- Biotechnology
Background:
- Small molecule inhibitors targeting growth factor receptors and somatic mutations in tyrosine kinases have revolutionized cancer therapy.
- Digital microscopy is a crucial tool for surgical pathology, transforming lab workflows and diagnostic capabilities.
- Digital pathology advancements enhance pathologists' roles in diagnostics and personalized targeted medicine.
Purpose of the Study:
- To describe the current state of digital microscopy in quantitative immunohistochemistry for personalized targeted cancer therapy.
- To review the application of digital microscopy in analyzing biomarkers such as HER-2, EGFR, KRAS, and BRAF.
- To highlight the role of digital pathology in diagnosing breast, non-small lung, and colorectal cancers.
Main Methods:
- Literature review on digital microscopy and quantitative immunohistochemistry.
- Analysis of digital image analysis platforms for diagnostic pathology.
- Case study review of biomarkers (HER-2, EGFR, KRAS, BRAF) in common cancers.
Main Results:
- Digital microscopy and image analysis significantly improve the quantification of biomarkers.
- The technology enhances the accuracy and efficiency of immunohistochemistry for targeted therapy selection.
- Digital pathology facilitates personalized medicine by providing precise biomarker data.
Conclusions:
- Digital microscopy is integral to modern quantitative immunohistochemistry for personalized targeted cancer therapy.
- The technology offers improved diagnostic performance and workflow efficiency in pathology labs.
- Digital pathology empowers pathologists to contribute more effectively to precision oncology.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:18Cancer
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...